Daniel Knowles
Midwest correspondent at The Economist, in Chicago. Before that, in London, Mumbai, Nairobi and DC.
Buy my book: shorturl.at/BJOUV
Reach me on Signal: dlknowles.12
- This is a really interesting piece, and these points are ones I notice a lot in the discourse around GLP-1 drugs: much of the antipathy to them is in & of itself fatphobia, anger or anxiety that takers are “cheating” their way out of the fat = lazy, slim = hard work paradigm.
-
View full threadfeel like it's also hard to eat the normal amount of healthy, food shopping there is either "these sausages are two dollars and somehow just fat, sugar and additives" or "please pay fifteen dollars for 100g of pasta made exclusively from mung beans", which....not that much in between
- Exactly
- I'm not even talking about the healthcare system here. I am talking about the built environment, primarily. It's so hard to live healthily in a place where you can't even *walk* (which is not my neighbourhood but is most of America)
- I am all for people having access to these drugs! But I wish somebody was actually taking seriously the environment that makes them necessary
- It is a real problem right now that just reporting the news accurately makes you sound like a hysterical partisan
- "Countries and businesses" is a nice elision. Exporters are very unlikely to eat the tariffs, because volume manufacturing is a highly competitive low-margin game. But American importing businesses probably will, short term, eat some share of tariffs rather than raise prices
- 56% of traffic in the City of London is now bicycles (I assume that is as a percentage count of individual vehicles)
- Was in town for the first time in a while..the transformation in air quality is outstanding
- Yeah it's also *so quiet*. Strikes me now whenever I am back, how peaceful London seems compared to anywhere in Chicago
